Inflammatory Breast Cancer Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Clinical Trials

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Conditions:   HER2-negative Breast Cancer;   Inflammatory Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast CancerInterventions:   Drug: Romidepsin;   Drug: AbraxaneSponsors:   Thomas Jefferson University;   Celgene CorporationRecruiting - verified May 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 5, 2013 Category: Research Source Type: clinical trials

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Conditions:   HER2-negative Breast Cancer;   Inflammatory Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast CancerInterventions:   Drug: Romidepsin;   Drug: AbraxaneSponsors:   Thomas Jefferson University;   Celgene CorporationRecruiting - verified October 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 5, 2013 Category: Research Source Type: clinical trials

Afatinib (BIBW2992) in HER2-overexpressing Inflammatory Breast Cancer
Condition:   Breast NeoplasmsInterventions:   Drug: Afatinib once daily (OD);   Drug: Vinorelbine WeeklySponsor:   Boehringer IngelheimActive, not recruiting - verified September 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2011 Category: Research Source Type: clinical trials

Afatinib (BIBW2992) in HER2-overexpressing Inflammatory Breast Cancer
Condition:   Breast NeoplasmsInterventions:   Drug: Afatinib once daily (OD);   Drug: Vinorelbine WeeklySponsor:   Boehringer IngelheimActive, not recruiting - verified November 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2011 Category: Research Source Type: clinical trials

Afatinib (BIBW2992) in HER2-overexpressing Inflammatory Breast Cancer
Condition:   Breast NeoplasmsInterventions:   Drug: Afatinib once daily (OD);   Drug: Vinorelbine WeeklySponsor:   Boehringer IngelheimActive, not recruiting - verified October 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2011 Category: Research Source Type: clinical trials

TKI258 for Metastatic Inflammatory Breast Cancer Patients
Condition:   Breast CancerIntervention:   Drug: DovitinibSponsors:   M.D. Anderson Cancer Center;   NovartisActive, not recruiting - verified December 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 15, 2010 Category: Research Source Type: clinical trials